About Oxolife
Oxolife is a company based in Barcelona (Spain) founded in 2013 by Ignasi Canals Almazan and Agnes Arbat. Oxolife has raised $7.04 million across 5 funding rounds from investors including EIT Health, CDTI and Ciencia. Oxolife offers products and services including Implantation Enhancement Drug. Oxolife operates in a competitive market with competitors including Sprout Pharmaceuticals, OvaScience, Hope Medicine, Rejoni and ObsEva, among others.
- Headquarter Barcelona, Spain
- Founders Ignasi Canals Almazan, Agnes Arbat
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.04 M (USD)
in 5 rounds
-
Latest Funding Round
$2.95 M (USD), Grant
Feb 23, 2026
-
Investors
EIT Health
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oxolife
Oxolife offers a comprehensive portfolio of products and services, including Implantation Enhancement Drug.
Drug improves embryo implantation to boost live birth rates in IVF
Funding Insights of Oxolife
Oxolife has successfully raised a total of $7.04M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $2.95 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Oxolife
Oxolife has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include EIT Health, CDTI and Ciencia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Inveready is recognized as a leading Spanish financial services firm.
|
Locked | Locked | Locked | |
|
BStartup Banco Sabadell is focused on providing banking and investment services to startups.
|
Locked | Locked | Locked | |
|
Healthcare startups are accelerated and incubated through specialized programs.
|
Locked | Locked | Locked |
Investor details for Oxolife
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oxolife
Investment portfolio details for Oxolife
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oxolife
Detailed financials for Oxolife
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oxolife Comparisons
Peer comparison for Oxolife
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oxolife
Oxolife operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sprout Pharmaceuticals, OvaScience, Hope Medicine, Rejoni and ObsEva, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs for hypoactive sexual desire disorder in women are developed.
|
|
| Locked | Locked | Locked |
Developer of new fertility treatments for women
|
|
| Locked | Locked | Locked |
Monoclonal antibodies are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for women's health conditions are developed using innovative hydrogels.
|
|
| Locked | Locked | Locked |
Therapeutics for women's reproductive health and pregnancy are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for fertility and menopause treatments are developed.
|
Detailed competitors of Oxolife
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oxolife
Complete news archive for Oxolife
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oxolife
Oxolife was founded in 2013 and raised its 1st funding round 7 years after it was founded.
Oxolife is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Agnes Arbat is the current CEO of Oxolife. They have also founded this company.
Oxolife is a funded company, having raised a total of $7.04M across 5 funding rounds to date.
Oxolife was founded in 2013 in Barcelona, Spain, as a biotechnology company specializing in female fertility treatments. An oral drug, OXO-001, is being developed to address implantation failure and early pregnancy loss, key barriers in assisted reproductive technologies. Studies are also underway on its application for infertility linked to polycystic ovary syndrome. Operations center on clinical advancement and regulatory processes in the reproductive health sector.
Oxolife's top competitors include Sprout Pharmaceuticals, Granata Bio and Rejoni.
Oxolife offers Implantation Enhancement Drug.
Oxolife has 6 investors. Key investors include EIT Health, CDTI, Ciencia, Inveready, and BStartup Banco Sabadell.